Abstracts

Citation

Michael Boivin, Miriam Chernoff, Jane Lindsey, Bonnie Zimmer, Barbara Laughton, Celeste Joyce, Katie McCarthy, Pim Brouwers, Patrick Jean-Philippe, Sonia Lee, Joan Coetzee, Avy Violari, Mark Cotton, Paul Palumbo. Initial findings from IMPAACT P1104s: a neuropsychological evaluation of HIV-infected and uninfected children in sub-Saharan Africa. Presented at: 7th International Workshop on HIV Pediatrics 2015.

Citation

Michael Boivin, Miriam Chernoff, Jane Lindsey, Bonnie Zimmer, Barbara Laughton, Celeste Joyce, Katie McCarthy, Pim Brouwers, Patrick Jean-Philippe, Sonia Lee, Joan Coetzee, Avy Violari, Mark Cotton, Paul Palumbo. Initial findings from IMPAACT P1104s: a neuropsychological evaluation of HIV-infected and uninfected children in sub-Saharan Africa. Presented at: 7th International Workshop on HIV Pediatrics 2015.

Citation

Initiation of Antiretroviral Treatment in Women after Delivery Can Induce Multi-class Drug Resistance in Breastfeeding HIV-infected Infants: Findings from the PEPI-Malawi trial. Presented at: 18th Conference on Retroviruses & Opportunistic Infections.

Citation

Brenda C. Kakayi, Patricia DeMarrais, Kristin Baltrusaitis, Lynda Stranix-Chibanda, Clemensia Nakabiito, Vivian Rexroad, Maxensia Owor, Sufia Dadabhai, Dhayendre Moodley, Friday Saidi, Avy Violari, Gerhard Theron, Takara Leah Stanley, Mary Glenn Fowler. Insulin-like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected. Presented at: CROI 2025; 2025 Mar 10; San Francisco, CA.

Citation

R Kreitchmann, A Stek, B Best, E Capparelli, J Wang, DE Shapiro, N Chakhtoura, S Burchett, M Mirochnick. Interaction between etonogestrel-releasing implant and 3 antiretroviral regimens. Presented at: CROI 2017; 2017 Feb 14.

Citation

Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (CT) Formulation in Children 2-5 Years. Presented at: 18th Conference on Retroviruses & Opportunistic Infections.

Citation

Interim Results from IMPAACT P1066: Raltegravir Oral Granules Formulation in Children 6 months to <2 Years of Age. Presented at: 19th Conference on Retroviruses and Opportunistic Infections.

Citation

Sharon Appelbaum Nachman, M.D., Edward P. Acosta, Pharm.D., Pearl Samson, M.S., Hedy Teppler, M.D., B. Homony, Terence Fenton, Ed.D., Edward Handelsman, M.D., Carol J. Worrell, M.D., Bobbie L. Graham, B.S., Andrew A. Wiznia, M.D. Interim Results from P1066: Raltegravir (RAL) Oral Chewable Tablet (OCT) Formulation in Children 6-11 Years. Presented at: 17th Conference on Retroviruses & Opportunistic Infections.

Citation

S. Nachman, E. Andersen-Nissen, A. Gartland, J. Hural, M.J. McElrath, Z. Shi, J. Ishmukhamedov, A Coletti, Diaz Granados C , C. Worrell, P Jean-Philippe, M. Cotton, L. Fairlie, A. Violari, the P1113 study team. Interim safety and immunogenicity results IMPAACT P1113: Phase I/II Study of AERAS-404 In BCG-Primed Infants. Presented at: TB Vaccines Fourth global Forum.

Citation

Donald J. Brambilla, Ph.D. Interkit Differences in Plasma HIV-1 RNA Levels in Mothers Enrolled in WITS/ACTG 076.